Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Candesartan Cilexetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.79 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.79 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.79 |
| ▸ | PPARG | P37231 | 2/20 | 0.79 |
| ▸ | HTR2B | P41595 | 2/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | ESR1 | P03372 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | PGR | P06401 | 1/20 | 0.79 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candesartan Cilexetil SCHEMBL1021483 | 1.00 | NAE1 (0.79) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL16949997 | 1.00 | NAE1 (0.79) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL3968703 | 1.00 | NAE1 (0.79) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL6515280 | 0.99 | NAE1 (0.78) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL474557 | 0.97 | AGTR2 (0.76) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL1775074 | 0.97 | NAE1 (0.75) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL15544662 | 0.94 | NAE1 (0.71) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| SCHEMBL1459137 | 0.94 | AGTR1 (0.72) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL1463446 | 0.94 | AGTR2 (0.70) | NAE1AGTR2CYP3A4ADORA3ADRA2B | |
| Candesartan Cilexetil SCHEMBL3944894 | 0.93 | NAE1 (0.69) | NAE1AGTR2CYP3A4ADORA3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12817 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4638742-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-29 | — | — | EP | claimed |
| US-12409173-B2 | Repurposing FDA-approved drugs as a novel cancer therapeutic avenue through inhibition of PRMT5 | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-09-09 | — | — | US | claimed |
| CN-120142485-A | Detection method of impurity hydrazine hydrate in candesartan cilexetil intermediate | 珠海润都制药股份有限公司 | 2025-06-13 | — | — | CN | claimed |
| US-5508297-A | ADMINISTERING A BENZIMIDAZOLE DERIVATIVE; AFTERTREATMENT FOR ANGIOPLASTY, RESTENOSIS FROM BYPASS SURGERY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-16 | — | — | US | claimed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | claimed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |
| EP-0622077-A1 | Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| EP-0612523-A1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0546358-A2 | Pharmaceutical compositions with angiotensin-II-antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-16 | — | — | EP | claimed |
| US-5196444-A | Angiotensin/II/ antagonists; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-23 | — | — | US | claimed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | claimed |